Lee, M.-F.M.-F.LeeLai, C.-S.C.-S.LaiCheng, A.-C.A.-C.ChengHou, J.-S.J.-S.HouBadmaev, V.V.BadmaevHo, C.-T.C.-T.HoMIN-HSIUNG PAN2018-09-102018-09-102015http://www.scopus.com/inward/record.url?eid=2-s2.0-84948716756&partnerID=MN8TOARShttp://scholars.lib.ntu.edu.tw/handle/123456789/391082Krill oil (KO) is rich in omega-3 long-chain polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic acid. Previous studies have shown that KO supplementation alleviated hepatic steatosis in rodents. Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil) is an important source of fucoxanthin and punicic acid. Our recent work indicated that xanthigen (Xan) significantly suppressed 3T3-L1 preadipocyte differentiation and lipid accumulation. Here we investigated the effect of KO and Xan on lipid accumulation in HepG2 liver cancer cells and on high fat diet (HFD)-induced obesity in C57BL/6J mice. KO potently inhibited triacylglycerol accumulation in Hep G2 cells. Supplementation with 2.5% KO or Xan effectively reduced HFD-induced body weight gain and adipose mass increase without affecting food intake, and improved diet-induced hepatic steatosis. In summary, KO and Xan may act as novel agents for the treatment of diet-induced obesity and steatosis. © 2014 Elsevier Ltd.High-fat diet; Krill oil; Non-alcoholic fatty liver disease; Obesity; Steatosis; Xanthigen[SDGs]SDG3[SDGs]SDG14journal article10.1016/j.jff.2014.10.015